129 related articles for article (PubMed ID: 2685142)
1. [Clinical studies of long-term administration of OK-432 in patients with gynecologic cancer].
Mano T; Kawamoto K; Miyake T; Torigoe T
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Sep; 41(9):1439-45. PubMed ID: 2685142
[TBL] [Abstract][Full Text] [Related]
2. [A double blind study of the evaluation of the optimal dose and its frequency in oral administration of OK-432 (Picibanil) by immunological parameters (the 1st report)].
Shiraishi T; Nio Y; Imai S; Tsubono M; Morimoto H; Tseng CC; Tobe T; Tanaka T; Kitamura O; Sakanashi S
Nihon Gan Chiryo Gakkai Shi; 1990 Apr; 25(4):799-811. PubMed ID: 2196311
[TBL] [Abstract][Full Text] [Related]
3. [Immunochemotherapy of resectable lung cancer--a preliminary study on a comparison of the control, levamisole, and OK-432].
Okayasu T; Kashimura Y; Matano J; Kawabata M; Takeoka T; Hashimoto M; Tanabe T
Gan To Kagaku Ryoho; 1982 Sep; 9(9):1646-52. PubMed ID: 6764120
[TBL] [Abstract][Full Text] [Related]
4. [Adjuvant immunochemotherapy with long-term OK-432 administration in colorectal cancer].
Kikkawa N; Sasai H; Kawahara T
Gan To Kagaku Ryoho; 1984 Oct; 11(10):2163-9. PubMed ID: 6486832
[TBL] [Abstract][Full Text] [Related]
5. Final report of a randomized controlled study with streptococcal preparation OK-432 as a supplementary immunopotentiator for laryngeal cancer.
Kimura T; Suzuki K; Motai H; Miyamoto N; Tsuge I; Ito Y; Baba S
Acta Otolaryngol Suppl; 1996; 525():135-41. PubMed ID: 8908288
[TBL] [Abstract][Full Text] [Related]
6. [The clinical value of long-term administration of OK-432 in head and neck cancer].
Mitarai K; Tsukuda M; Tamamushi N; Mochimastu I; Kubota A; Sawaki S
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):945-50. PubMed ID: 3963858
[TBL] [Abstract][Full Text] [Related]
7. [Randomized controlled study of OK-432 in the treatment of cancerous pleurisy].
Urata A; Nishimura M; Ota K
Gan To Kagaku Ryoho; 1983 Jun; 10(6):1497-503. PubMed ID: 6409006
[TBL] [Abstract][Full Text] [Related]
8. Gynecologic cancers: factors affecting survival after pulmonary metastasectomy.
Clavero JM; Deschamps C; Cassivi SD; Allen MS; Nichols FC; Barrette BA; Larson DR; Pairolero PC
Ann Thorac Surg; 2006 Jun; 81(6):2004-7. PubMed ID: 16731120
[TBL] [Abstract][Full Text] [Related]
9. [A controlled study of surgical adjuvant chemoimmunotherapy with FT-207 and OK-432 for advanced stomach cancer: the fourth study].
Yamamura Y; Yasue M; Nakazato H; Ota K
Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):541-8. PubMed ID: 3923941
[TBL] [Abstract][Full Text] [Related]
10. [Studies on the enhancement of anti-tumor activity in patients with cervical cancer by local administration of OK-432].
Yamada Y; Yamamoto K; Wakita K; Shiraki S; Noda K
Gan To Kagaku Ryoho; 1986 Dec; 13(12):3427-31. PubMed ID: 3789753
[TBL] [Abstract][Full Text] [Related]
11. [A double blind study to evaluate the optimal dose and its frequency for oral administration of OK-432 (picibanil) by immunological parameters (the 2nd report)].
Shiraishi T; Nio Y; Imai S; Tsubono M; Morimoto H; Tseng CC; Tobe T; Tanaka T; Kitamura O; Sakanashi S
Nihon Gan Chiryo Gakkai Shi; 1990 May; 25(5):997-1012. PubMed ID: 2202770
[TBL] [Abstract][Full Text] [Related]
12. [Effect of endoscopical administration of OK-432 in 4 patients with advanced esophageal or gastric cancer].
Satomi T; Inoue S; Fujita T; Ogawa S; Honda H; Hayashi M
Gan No Rinsho; 1989 Mar; 35(4):512-5. PubMed ID: 2541269
[TBL] [Abstract][Full Text] [Related]
13. Clinical value of immunotherapy with the streptococcal preparation OK-432 in non-small cell lung cancer.
Watanabe Y; Iwa T
J Biol Response Mod; 1987 Apr; 6(2):169-80. PubMed ID: 3585412
[TBL] [Abstract][Full Text] [Related]
14. [The effect of OK-432 in the treatment of primary lung cancer].
Kishimoto T; Okada K
Gan To Kagaku Ryoho; 1987 Apr; 14(4):1051-6. PubMed ID: 3494430
[TBL] [Abstract][Full Text] [Related]
15. [A randomized controlled study to compare bladder instillation therapy of anticancer agents and combination therapy with OK-432 injection in prevention of post-TUR recurrence of bladder cancer].
Nishio S; Yoshihara H; Yamamoto K; Kishimoto T; Maekawa M
Hinyokika Kiyo; 1988 Nov; 34(11):2053-7. PubMed ID: 2468266
[TBL] [Abstract][Full Text] [Related]
16. [Immunotherapy, with OK-432 for cases of nasopharyngeal carcinoma].
Tsukuda M; Tamamushi N; Mochimatsu I; Mitarai K; Kaneko M; Sawaki S
Gan To Kagaku Ryoho; 1986 Jan; 13(1):53-9. PubMed ID: 3942399
[TBL] [Abstract][Full Text] [Related]
17. [Clinical study on the effect of adjuvant immunochemotherapy using OK-432 and 5-FU in pharyngeal and laryngeal cancers].
Yajin K; Harada Y; Tagashira N; Suzuki M; Hirakawa K; Sera K; Nakata M; Takebayashi S; Okazaki H; Yashiki T
Gan To Kagaku Ryoho; 1988 Jun; 15(6):1921-7. PubMed ID: 3289502
[TBL] [Abstract][Full Text] [Related]
18. [New combined therapy of radiation and local administration of OK-432 for esophageal cancer--local control rate and two-year survival rate].
Mukai M; Morita S; Tsunemoto H
Nihon Gan Chiryo Gakkai Shi; 1990 Jan; 25(1):94-7. PubMed ID: 2324590
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy using the streptococcal preparation OK-432 for the treatment of uterine cervical cancer. Cervical Cancer Immunotherapy Study Group.
Noda K; Teshima K; Tekeuti K; Hasegawa K; Inoue K; Yamashita K; Sawaragi I; Nakajima T; Takashima E; Ikeuchi M
Gynecol Oncol; 1989 Dec; 35(3):367-72. PubMed ID: 2689304
[TBL] [Abstract][Full Text] [Related]
20. [Study on adjuvant immunochemotherapy with long-term OK-432 administration in colorectal cancer].
Kikkawa N; Kawahara T
Gan To Kagaku Ryoho; 1988 Jun; 15(6):1881-5. PubMed ID: 3382240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
